Wordt geladen...
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
Rivastigmine (or Exelon) is a cholinesterase inhibitor, currently used as a symptomatic treatment for mild-to-moderate Alzheimer’s disease (AD). Amyloid-β peptide (Aβ) generated from its precursor protein (APP) by β-secretase (or BACE1) and γ-secretase endoproteolysis. Alternative APP cleavage by α-...
Bewaard in:
| Gepubliceerd in: | Transl Psychiatry |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Nature Publishing Group UK
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7026402/ https://ncbi.nlm.nih.gov/pubmed/32066688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41398-020-0709-x |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|